Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Inhibition of tumor necrosis factor (TNF) is an effective treatment for rheumatoid arthritis (RA), but safety concerns about malignancy remain. The aim of this study was to evaluate cancer risk in RA patients treated with TNF inhibitors (TNFi), based on Korean Nationwide Health Insurance claims data. Methods: Patients with seropositive RA were selected from the health insurance database containing all citizens’ medical information, based on both RA diagnosis codes and medications. Between 2010 and 2014, RA patients treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and TNFi were enrolled and followed up. We compared the cancer incidence between patients treated with TNFi and csDMARDs using incidence rate ratios (IRRs) after adjustment for age, gender, and observational periods. Results: Of 45,423 selected patients with seropositive RA, 2,337 were treated with TNFi and 43,086 were treated with csDMARDs. The TNFi group was younger and was followed-up for a longer duration. During the observational period, 1,732 and 49 cases of cancer were detected in patients treated with csDMARDs and TNFi, respectively. Old age and male sex were associated with cancer occurrence. Adjusted IRRs for all cancers and common cancers demonstrated that cancer incidence did not differ significantly between the TNFi group and csDMARDs group (IRR = 0.913 for all cancers, p = 0.546). Conclusions: This study revealed that cancer incidence was similar in RA patients treated with TNFi and csDMARDs. Anti-TNF therapy may be a safe therapeutic option for RA treatment, in terms of malignancy.
Abstract
Background/Aims: Inhibition of tumor necrosis factor (TNF) is an effective treatment for rheumatoid arthritis (RA), but safety concerns about malignancy remain. The aim of this study was to evaluate cancer risk in RA patients treated with TNF inhibitors (TNFi), based on Korean Nationwide Health Insurance claims data. Methods: Patients with seropositive RA were selected from the health insurance database containing all citizens’ medical information, based on both RA diagnosis codes and medications. Between 2010 and 2014, RA patients treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and TNFi were enrolled and followed up. We compared the cancer incidence between patients treated with TNFi and csDMARDs using incidence rate ratios (IRRs) after adjustment for age, gender, and observational periods. Results: Of 45,423 selected patients with seropositive RA, 2,337 were treated with TNFi and 43,086 were treated with csDMARDs. The TNFi group was younger and was followed-up for a longer duration. During the observational period, 1,732 and 49 cases of cancer were detected in patients treated with csDMARDs and TNFi, respectively. Old age and male sex were associated with cancer occurrence. Adjusted IRRs for all cancers and common cancers demonstrated that cancer incidence did not differ significantly between the TNFi group and csDMARDs group (IRR = 0.913 for all cancers, p = 0.546). Conclusions: This study revealed that cancer incidence was similar in RA patients treated with TNFi and csDMARDs. Anti-TNF therapy may be a safe therapeutic option for RA treatment, in terms of malignancy.
참고문헌 (27)
- Singh JA, "2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis", Arthritis Rheumatol, 68, pp.1~26 (2016)
- Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update", Ann Rheum Dis, 73, pp.492~509 (2014)
- Nam JL, "Efficacy of biological disease-modifying antirheumatic drugs : a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis", Ann Rheum Dis, 73, pp.516~528 (2014)
- Lebrec H, "Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk", Curr Med Res Opin, 31, pp.557~574 (2015)
- Balkwill F, "Tumour necrosis factor and cancer", Nat Rev Cancer, 9, pp.361~371 (2009)
- Green S, "Partial purification of a serum factor that causes necrosis of tumors", Proc Natl Acad Sci U S A, 73, pp.381~385 (1976)
- Carswell EA, "An endotoxin-induced serum factor that causes necrosis of tumors", Proc Natl Acad Sci U S A, 72, pp.3666~3670 (1975)
- Bongartz T, "Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies : systematic review and meta-analysis of rare harmful effects in randomized controlled trials", JAMA, 295, pp.2275~2285 (2006)
- Lopez-Olivo MA, "Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy : a meta-analysis", JAMA, 308, pp.898~908 (2012)
- Mercer LK, "Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy : results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis", Ann Rheum Dis, 74, pp.1087~1093 (2015)
- Buchbinder R, "Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy : analysis of the Australian Rheumatology Association Database(ARAD)prospective cohort study", BMC Musculoskelet Disord, 16, pp.309~ (2015)
- Wu CY, "The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists : a nationwide cohort study", Arthritis Res Ther, 16, pp.449~ (2014)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- "Operational structure of Korea health care system" (2013)[URL]
- Jung SM, "Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy : a nationwide study in South Korea, a country with an intermediate tuberculosis burden", Int J Rheum Dis, 18, pp.323~330 (2015)
- Cho SK, "Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database", Rheumatol Int, 33, pp.2985~2992 (2013)
- Mariette X, "Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies : a systematic review and meta-analysis", Ann Rheum Dis, 70, pp.1895~1904 (2011)
- Chen YJ, "The risk of cancer in patients with rheumatoid arthritis : a nationwide cohort study in Taiwan", Arthritis Rheum, 63, pp.352~358 (2011)
- Kim YJ, "Mortality and incidence of malignancy in Korean patients with rheumatoid arthritis", J Rheumatol, 39, pp.226~232 (2012)
- "Cancer incidence" (2012)[URL]
- Chen Y, "Malignancy risk of anti-tumor necrosis factor alpha blockers : an overview of systematic reviews and meta-analyses", Clin Rheumatol, 35, pp.1~18 (2016)
- Grivennikov SI, "Immunity, inflammation, and cancer", Cell, 140, pp.883~899 (2010)
- Abasolo L, "Cancer in rheumatoid arthritis : occurrence, mortality, and associated factors in a South European population", Semin Arthritis Rheum, 37, pp.388~397 (2008)
- Baecklund E, "Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis", Arthritis Rheum, 54, pp.692~701 (2006)
- 오창모, "Age-Period-Cohort Analysis of Thyroid Cancer Incidence in Korea", Cancer Research and Treatment, 47(3), pp.362~369 (2015), 대한암학회[DOI]
- Simon TA, "Incidence of malignancy in adult patients with rheumatoid arthritis : a meta-analysis", Arthritis Res Ther, 17, pp.212~ (2015)
- "Korean College of Rheumatology Biologics Registry" (2006)[URL]